The Massachusetts CCC’s report shows that between Jan. 1 and Dec. 18, 2022, the state collected $1.42 billion in adult-use sales. In a breakdown...

The Massachusetts CCC’s report shows that between Jan. 1 and Dec. 18, 2022, the state collected $1.42 billion in adult-use sales. In a breakdown of sales by month, the state collected a fairly steady amount of sales, the highest being $132.4 million in July and $130.8 million in August, and the lowest with $110.1 million in February and only $73 million in December (since recording ended on Dec. 18, this sales data is lower).

The last week of sales by day leading up to Dec. 25 were notably high, starting at $3.2 million on Monday, Dec. 12 reaching a height of $5.1 million on Saturday, Dec. 17, and dropping to $4 million on Dec. 18. Consumers mainly purchased flower during this week specifically, with a total of over $11 million, followed by vape-related products at $6 million, and pre-rolls and edibles nearly the same, both around $4 million each.

Massachusetts legalized adult-use cannabis in November 2018, and since then the state has collected $3.9 billion in total gross sales. It first reached the $1 billion mark in October 2020, then $2 billion in July 2021, and $3 billion in May 2022.

Medical cannabis sales in 2022 during the same period reached $260.2 million, although a gradual decline is seen after the highest medical sales months of March and April, which collected $24.7 million and $24.4 million respectively. The Massachusetts CCC’s graph generally shows a decrease in sales from that point, down to $20.6 million in November, and finally $12.1 million in December.

Gross medical cannabis sales just hit $929.6 million this December, which still reflects steady overall growth since November 2018. Although medical cannabis went live in Massachusetts in January 2013, sales data prior to November 2018 is not available prior to when the CCC took control over the Medical Use of Marijuana Program.

Over the past four years since adult-use cannabis began, the cost of flower has decreased over time. With a few exceptions in March, April and May 2020 due to the pandemic, the average price of flower per gram has remained around $14 until June 2021. After that point, price per gram continued to decrease every month, landing at $7.76 per gram in November 2022, and increasing slightly to $8.07 in November 2022. This coincides with CCC data showing the state’s history with cannabis cultivation. In terms of plants harvested, the state began with only 79 plants in November 2018; followed by 247,793 in November 2019; 699,938 in November 2020; 1,413,311 in November 2021; and finally a huge jump to 2,655,494 plants in November 2022.

According to Boston.com, Brandon Pollock, CEO of Theory Wellness, said that the completion of many cultivation facilities over the last year has contributed to the imbalance of supply and demand. “The last 12 months have been fairly drastic. I’d say on the wholesale market, prices might be down approximately 50% in one year, which is, for folks that are only on the cultivation side of the business, especially difficult,” Pollock told Boston.com.

Joseph Lekach, CEO of Apothca, also explained that this imbalance has been present for some time. “A year and a half, two years, three years ago, it wasn’t good either. It was unbalanced to the high side, now it’s unbalanced for the low side. So this is temporarily good from a customer’s perspective,” Lekach told Boston.com. “But a lot of manufacturers and cultivators will cut costs wherever they can just to stay alive. You’re going to have an inferior product coming out. It’s a double-edged sword.”

Lekach also estimated that based on this current trend, many cannabis companies will be out of business by next year. “We have no idea where the bottom is going to be. I think that there’s a lot of companies suffering because of this,” said Lekach. “I think you’re going to see a lot of companies going out of business probably next year and into 2024.”

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

No comments so far.

Be first to leave comment below.

( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )